Indivior plc
http://indivior.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Indivior plc
Parexel Execs On Obesity Drug Hurdles, Parexel GPT, India RWD Opportunity
Parexel’s chief strategy officer Kushal Gohil, Clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India, in the second of this two-part interview with Scrip.
Click Targets ‘Best-In-Class Digital Therapy For Chronic Weight Management’ With Better Therapeutics Acquisition
Click will fold Better Therapeutics’ FDA-cleared AspyreRx prescription digital therapeutic into R&D for its own CT-181, which promises to optimize obesity treatment in combination with drugs such as GLP-1s and provide "valuable real-world data insights for providers and payers." Better Therapeutics shuttered its operations in March, signaling continued challenges for digital medicine innovators.
Addex Gets Creative To Secure Funding And Its Future
Addex Therapeutics’ Tim Dyer has seen the company through 22 years of ups and downs. He has kept the company afloat, and recently did the same by spinning out a new company.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Indivior Inc.
- Indivior UK Limited
- Reckitt Benckiser Pharmaceuticals Inc. (RBP)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice